|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.615 USD | +0.31% |
|
-0.93% | +4.90% |
| Apr. 22 | Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day | |
| Mar. 25 | Lexicon Pharmaceuticals Files Prospectus for Secondary Offering | MT |
May 26 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's drug as a broad treatment for all heart failure patients, including adults with type 2 diabetes, the company said on Friday. (Reporting by Khushi Mandowara and Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 736.9 USD | -1.18% | -2.11% | 672B | ||
| 87.7 EUR | -1.29% | +1.76% | 119B | ||
| 1.615 USD | +0.31% | -0.93% | 396M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +4.90% | 396M | |
| -1.71% | 105B | |
| +3.56% | 97.5B | |
| +1.86% | 22.19B | |
| -16.51% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.48% | 14.52B | |
| +5.10% | 14.09B | |
| +25.37% | 10.99B |
LEXICON PHARMACEUTICALS, INC. 
